The case for & against
Bull & Bear analysis
Bullish
Donaldson Company, Inc. (NYSE: DCI) is a leading global manufacturer of filtration systems specializing in industrial, mobile, and life sciences applications. With a strong focus on innovation and strategic acquisitions, such as the recent purchase of FACET Filtration, Donaldson is positioned in critical markets including aerospace, automotive, and food and beverage. The company's commitment to enhancing operational efficiency and meeting complex filtration challenges positions it strongly within the filtration industry.
Bull says
- ↑Recorded FY26 revenues of $3.89B (+5.3% YoY), EPS up 8% to $3.98 and operating margin at 16%.
- ↑Management projects FY27 sales >$4.1B (+7.5%) supported by robust order backlog.
- ↑FACET acquisition to add ~$110M revenue and expand aerospace & defense offerings.
- ↑Announces $250M in dividends and buybacks; dividend yield ~5.1%.
- ↑Strong earnings yield factor and low leverage support valuation.
- ↑Stable price volatility appeals to risk-averse investors.
Bear says
- ↓Net debt/equity at 61% increases interest burden and limits flexibility.
- ↓Negative growth momentum and weak analyst revisions signal sluggish performance.
- ↓Low institutional ownership reflects tepid market confidence in growth prospects.
- ↓Ongoing supply chain disruptions and 40bp gross margin pressure in aerospace.
- ↓Rising competition from emerging filtration technologies may erode market share.
- ↓Inflationary cost pressures and operational headwinds could weigh on margins.
Investment themes with DCI
High Dividend Yield↓ -0.51%
Companies paying above-average dividends
AVGO · JPM · XOM
Earnings Call · Q4 2025 · Mgmt. Guidance
Updated 08-26-2026neutral
Transcript signals
Bull points
- In fiscal 2025, we grew sales to an all time high of $3.7 billion with growth across all segments.
- expanded operating profit margin to a record 15.7% with an incremental margin of nearly 30% delivered earnings per share of $3.68, towards the higher end of the guidance range we laid out at the beginning of the year.
- returned $465 million to shareholders largely through the repurchase of 4% of our shares outstanding while increasing our dividend 11% and focused our cost structure, including in life sciences, and made progress towards footprint optimization, strengthening our foundation for future profitability while still investing for growth.
Bear points
- On-road sales of $26 million declined 20% as a result of cyclical declines in global truck production.
- Then the second piece of this would be, of the bioprocessing story, would be the downstream application piece where we're creating new products to bring those out to market to create revenue and growth in that fashion. That is taking a little bit longer to get those projects to market.
- But it's really a replacement part story at this point in time for us because we continue to gain share as a result of our strategies, good execution. We do expect the U.S. to hold, and we continue to take first-hit share. But really, it's largely a replacement parts story within that business.
Read full transcript analysis ›